Viewing affirmative mentions of positive regulation of IL2 (H. sapiens) in LAK cells

Full-text article links are indicated by after the article reference.

Document Target Regulator Anatomy Sentence
Wang et al. (1990)IL-2LAK cellsIn certain extent the LAK cells in the patient increased IL-2 concentration during incubation, but it did not reach the normal level.
Clerigue et al. (1990)IL-2LAK cellsThe inhibitory activity from the initially non-cytotoxic/non-inhibitory BM population was rapidly induced by IL-2 activation, and preceded the generation of cytotoxic LAK cells in the culture.
Akiyoshi et al. (1988)IL 2LAK cellsBoth the ability to produce IL 2 and to generate LAK cells were shown to be significantly increased in SP cells when compared to PBM cells.
Sodhi and Basu (1992)IL-2lymphokine activated killer cellUp-regulation of IL-2 induced lymphokine activated killer cell activity by cisplatin and FK-565: involvement of calcium ion.
George et al. (1988)interleukin-2LAK cellGreatly increased expansion of LAK cell cultures could be achieved by short-term stimulation with monoclonal anti-CD3 antibodies in addition to interleukin-2 activation.
Galustian et al. (1994)IL-2LAKA novel finding was that SW enhanced the interleukin 2 (IL-2) beta chain receptor subunit expression on both LAK and NK cells to a greater extent than its enhancement of the IL-2R alpha (CD25 or TAC) receptor expression on LAK effectors.
Wanebo et al. (1993)IL-2LAK cellLAK cell function at low-dose IL-2 was depressed in 45% of the patients (9 of 20) and was restored by increased IL-2 (1,000 U/mL) or a combination of IL-2 and INF-alpha.
Ishimitsu and Torisu (1993)IL-2LAK cellUsing ELISA for hIL-5, the IL-5 level in the supernatant of LAK cell cultures increased dose dependently with increasing IL-2 concentrations.
Hancock et al. (1991)IL-2LAK cellLAK cell activity was induced with IL-2 in vitro in both BL/LL patients and in normal volunteers.
Atkins et al. (1988)interleukin-2LAK cellsThirty-four patients with advanced neoplasms who had received interleukin-2 and LAK cells were followed for at least four weeks after treatment.
Kimura and Yamaguchi (1997)IL-2LAK cellsThe patients of Group A received IL-2 and LAK cells after either chemotherapy or radiotherapy, and those in Group B received either no adjuvant therapy (curative cases) or radiotherapy or chemotherapy alone (noncurative cases), according to the causes of noncurative resection.
Horton et al. (1990)IL-2LAK cellSuch an approach could make IL-2/LAK cell therapy more accessible for cancer patients.
McCulloch et al. (1991)IL-2LAK cellsThe presence of LAK cells reduced the serum half-life of IL-2 significantly, but not to an extent able to account for the observed loss of IL-2 induced DTH enhancement.
Clark et al. (1990)IL-2LAK cellA second group of 22 cancer patients received IL-2 by continuous i.v. infusion at 3 x 10(6) units/m2 for 5 days during priming and an additional 5 days of IL-2 with the LAK cell phase of the treatment.
Eberlein and Schoof (1991)IL-2LAK cellExperience from a number of research centers can be generalized: LAK cell trials in humans have demonstrated that PBMCs activated with IL-2 possess reproducible antitumor activity in vitro.
Okamura et al. (1991)IL-2LAK cellsThese findings indicate that the addition of GM-CSF in the presence of IL-2 during the induction of LAK cells is useful for obtaining a larger number of effector cells which possess substantial cytotoxic activity.
Benyunes et al. (1993)IL-2LAK cellsIn a subsequent trial, five patients received IL-2 at 3.0 x 10(6) U/m2/day x 5 days, underwent leukapheresis for 3 days and received their LAK cells plus IL-2 (0.3 x 10(6) U/m2/day x 10 days).
Benyunes et al. (1995)IL-2LAK cellsThis paper presents the clinical results of 16 patients with ML, who participated in a study to determine whether LAK cells could be administered after ABMT with this IL-2 regimen, as well as 6 patients who received IL-2 alone after ABMT or PBSCT.
Hank et al. (1990)IL-2LAK cellsThese pharmacokinetic results, together with the IL-2 dose dependence of LAK activity generated in vivo shown in this report, suggest that a combination of treatment with bolus IL-2 infusions superimposed on continuous IL-2 infusion may transiently expose IL-2 dependent LAK cells, activated in vivo, to higher concentrations of IL-2, facilitating their in vivo cytotoxic potential.
Adibzadeh et al. (1992)IL-2LAK cellsHowever, lip-IL-2 was found to be markedly inferior to free natural or recombinant IL-2 for the induction of LAK cells from normal donors.
Munn and Cheung (1987)IL-2LAKActivation of ADCC was detected earlier than lymphokine activated killer cell (LAK) activity, required less IL-2 for optimum induction (50 versus 1000 units/ml), and was of equal or greater absolute magnitude (+10 to +200%) against the cell lines tested.
Munn and Cheung (1987)IL-2LAK cellsIL-2 activated ADCC may be of value alone or in conjunction with LAK cells in the therapy of tumors which bind the antibody 3F8.
Massumoto et al. (1996)IL-2LAK cellsA median of 35 days (range 25-58) after ABMT, they received a 5-day induction course of Roche IL-2 (9 x 10(6) U/m2/day) followed by apheresis, reinfusion of LAK cells, and a 10-day maintenance course of IL-2 (0.9 x 10(6) U/m2/day), all by continuous i.v. infusion.
Maruyama et al. (1990)IL-2LAK cellsKinetic study showed that the lysis of AM phi was proportional to the incubation time of MNCs with IL-2 and that LAK cells against AM phi required two days of in vitro culture with IL-2 for their induction.
Heaton et al. (1993)IL-2LAK cellsThese findings suggest that interaction of IL-2 with IL-2R beta gamma alone is sufficient for both proliferation and the generation of LAK, and that stimulation with subunit-specific IL-2 analogs results in differential regulation of the IL-2R alpha on human LAK cells.
Parhar et al. (1992)IL-2LAK cellsLAK cells induced with IL-2 alone had no significant suppressive effects on GM-CFU.
Favrot et al. (1990)IL-2LAK cellThe effect of IL-4 upon IL-2-induced LAK cell expansion is thus very different on PBMC pre-activated in vivo by alpha IFN + IL-2 therapy than on PBMC pre-treated in vitro with IL-2.
Paliard et al. (1989)IL-2lymphokine activated killer cellIn addition, IL-4 can enhance CTL activity in MLC, but blocks IL-2 induced lymphokine activated killer cell activity in PBL.
Sone et al. (1987)IL 2LAK cellRecombinant IFN-gamma did not affect AM-mediated suppression of LAK cell induction by IL 2.
Watanabe et al. (1993)IL-2LAK cellsADCC was activated by IL-2 earlier (1 day) than the generation of LAK cells (3-4 days), and at lower concentration of IL-2.
Kutza and Murasko (1996)IL-2LAK cellAge-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples.
Cesano et al. (1995)IL-2LAK cellsMoreover, the cytotoxic responses to recombinant human IL-2 and IL-12, measured 18 h after irradiation and cytokine addition, were normal in the case of TALL-104 cells but were abolished in the case of LAK cells.
Brooks and Rees (1988)rhIL-2LAKIn four out of six experiments there was a significant reduction of rhIL-2 induced LAK in the presence of rhIL-4, accompanied by a reduction of Tac antigen expression by rhIL-2 activated cells.
De et al. (1991)interleukin-2Lymphokine activated killer cellsLymphokine activated killer cells and interleukin-2 production in patients with cervical carcinoma.
Mitchell et al. (1989)lymphokinelymphokine activated killer cellsThis regimen appeared to be as effective in melanoma as those involving ex vivo activation of lymphokine activated killer cells, and was more tolerable than therapy with high doses of interleukin-2.
de Kroon et al. (1997)rhIL-2LAK cellAlthough the three CD8+ CTL clones and two CTL lines tested required rhIL-2 for their engraftment, the four LAK cell populations also engrafted in the absence of rhIL-2.
Fujioka and Sezai (1991)LymphokineLymphokine activated killer cellIncrease of LAK (Lymphokine activated killer cell) activity was observed during treatment with intra-arterial continuous infusion of rIL-2.
Froelich and Guiffaut (1986)lymphokinelymphokine activated killer cellsInduction of lymphokine activated killer cells in serum-free medium.
Watanabe et al. (1994)lymphokinelymphokine activated killer cellsCell cycle assessment of adoptive transferred lymphokine activated killer cells.
Moretta et al. (1991)IL-2LAK cellsUpon stimulation with IL-2, TCR gamma/delta+ cells, similar to other LAK cells, display an increase in their cytoplasmic granules together with a redistribution of cytoskeletal structures.
Riley et al. (1990)IL-2LAK cellsIgG, purified by affinity chromatography from ascitic fluids, from plasma of cancer patients, and from plasma of healthy donors, significantly inhibited IL-2 induction of LAK cells in a dose-dependent manner.
Lowrey et al. (1988)interleukin 2LAK cellsGranule-associated N-alpha-carbamazepine-L-lysine thiobenzyl ester-esterase activity increased in recombinant interleukin 2 expanded human LAK cells in parallel with cytotoxic activity for Raji tumor cell targets.
Lowrey et al. (1988)interleukin 2LAK cellsHuman LAK granules were synthesized in response to recombinant interleukin 2 activation and appeared in parallel with cytotoxicity for tumor targets, suggesting an important role for LAK granules in tumor cell cytotoxicity by human LAK cells.
Besana et al. (1991)interleukin-2LAK cellAutoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: correlation with tumor regression.
Gottlieb et al. (1989)IL-2LAKLAK precursor activity in peripheral blood also significantly increased during IL-2 infusion.
Tsujihashi et al. (1988)lymphokinelymphokine activated killer cellOn the other hand, the spontaneous lymphokine activated killer cell (LAK) activity of PBL and TIL was very low.
Lamm and Riggs (2000)IL-2LAK cellsGarlic is reported to stimulate immunity, including macrophage activity, natural killer and killer cells, and LAK cells, and to increase the production of IL-2, TNF, and interferon-gamma.
Pawelec et al. (1989)IL-2LAK cellIncreasing concentrations of IL-2 and/or culture duration also failed to improve LAK cell generation by patients.
Jin et al. (1989)IL-2LAK cellSimilarly, it was shown that phytohaemagglutini (PHA)-induced lymphoblasts up-regulate their surface expression of TLiSA1 and exhibit increased LAK activity in response to IL-2, and TGF beta inhibited both of these events; this IL-2-induced increase in LAK cell function was also inhibited by antibodies to TLiSA1.
Tsavaris et al. (2002)IL-2LAK cellThe present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.